Literature DB >> 8005676

Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.

D C Houpt1, G S Pfrommer, B J Young, T A Larson, T R Kozel.   

Abstract

Serum obtained from normal human subjects contains antibodies reactive in an enzyme-linked immunosorbent assay with the glucuronoxylomannan (GXM) of Cryptococcus neoformans. The frequency of occurrence of class-specific antibodies among normal subjects was 28% for immunoglobulin G (IgG), 98% for IgM, and 3% for IgA. Anti-GXM antibodies with kappa light chains occurred in 98% of normal subjects, while the occurrence of lambda light chains was 28%. Each of five subjects with high levels of anti-GXM IgG antibodies had readily detectable antibodies of the IgG2 isotype; two of the five subjects had readily detectable IgG1 antibody. An examination of sera from human immunodeficiency virus-infected patients showed that human immunodeficiency virus infection was accompanied by a significant decrease in the occurrence of IgM antibodies and anti-GXM antibodies with kappa light chains; these decreases occurred early in infection when CD4 counts were still > or = 500 cells per microliter. A slight but not statistically significant decrease in the occurrence of anti-GXM IgG antibodies was seen only in patients with CD4 levels of < 200 cells per microliter. Sera from normal subjects with high levels of anti-GXM IgG antibodies were examined to identify any contribution of the antibodies to complement activation or to opsonization of the yeast cells. An analysis of the kinetics for activation and binding of C3 to the yeast cell showed no pattern of quantitative or qualitative differences between sera with high or low levels of anti-GXM IgG antibodies. Phagocytosis studies showed that the naturally occurring IgG antibodies did not contribute to opsonization of the yeast cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005676      PMCID: PMC302892          DOI: 10.1128/iai.62.7.2857-2864.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

Authors:  T R Kozel; M A Wilson; G S Pfrommer; A M Schlageter
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Cryptococcus neoformans antibody levels in patients with AIDS.

Authors:  F Dromer; P Aucouturier; J P Clauvel; G Saimot; P Yeni
Journal:  Scand J Infect Dis       Date:  1988

3.  Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus.

Authors:  R S Klein; P A Selwyn; D Maude; C Pollard; K Freeman; G Schiffman
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

4.  Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.

Authors:  T R Kozel; G S Pfrommer; A S Guerlain; B A Highison; G J Highison
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

5.  Role of IgG and complement component C5 in the initial course of experimental cryptococcosis.

Authors:  F Dromer; C Perronne; J Barge; J L Vilde; P Yeni
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

6.  Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.

Authors:  A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

7.  Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis.

Authors:  D K Henderson; J E Bennett; M A Huber
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

8.  Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans.

Authors:  S M Levitz; D J DiBenedetto
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

9.  Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.

Authors:  T R Kozel; G S Pfrommer
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

10.  Benzoquinone activation of Cryptococcus neoformans capsular polysaccharide for construction of an immunoaffinity column.

Authors:  T R Kozel; C A Hermerath
Journal:  J Immunol Methods       Date:  1988-02-24       Impact factor: 2.303

View more
  43 in total

1.  Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.

Authors:  T C MacGill; R S MacGill; T R Kozel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Antibody response to Cryptococcus neoformans proteins in rodents and humans.

Authors:  L C Chen; D L Goldman; T L Doering; L a Pirofski; A Casadevall
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.

Authors:  Marcellene A Gates; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis.

Authors:  Dolan Champa Saha; Immaculata Xess; Wang Yong Zeng; David L Goldman
Journal:  Med Mycol       Date:  2008-03-10       Impact factor: 4.076

Review 5.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

6.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

7.  A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock.

Authors:  M Piccioni; C Monari; S Kenno; E Pericolini; E Gabrielli; D Pietrella; S Perito; F Bistoni; T R Kozel; A Vecchiarelli
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

8.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Mechanisms of inhibition of Cryptococcus neoformans by human lymphocytes.

Authors:  S M Levitz; E A North; M P Dupont; T S Harrison
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.